P09.05.B PARTICLE RE-IRRADIATION FOR THE TREATMENT OF RECURRENT INTRACRANIAL MENINGIOMAS

Abstract BACKGROUND Recurrent intracranial meningiomas have no unique treatment. Particle re-irradiation (reRT) is one of the therapeutic options available and the present study aims at investigating its oncological outcomes. MATERIAL AND METHODS A retrospective analysis was conducted on patients with recurrent intracranial meningiomas treated with both proton and carbon ion reRT from 2016 to 2024. Local control (LC) and overall survival (OS) were evaluated with the Kaplan-Meier method. For prognostic factors analysis the Log-Rank test for testing curve equality was performed and p-value was reported. Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS 20 patients were included, with 11 patients receiving carbon ion reRT and 9 patients receiving proton reRT. With a median follow-up of 22.8 months (range, 4.2-96.2), 5 patients experienced a local relapse after particle reRT. The 1- and 2-year LC was 88.2%, while 5-year LC was 52.3%. A statistically significant difference in terms of median LC was found between grade I and grade II/III meningiomas (40.6 vs 28.4 months, p = 0.0035). OS at 1 and 2 years were respectively 89.5% and 83.1%. There were no grade 3 or higher acute and late toxicities. Four patients developed radiation-induced brain necrosis (RBN), two patients an asymptomatic grade 1 RBN and two patients a grade 2 RBN positively treated with dexamethasone. CONCLUSION Particle reRT is a safe and promising option for recurrent intracranial meningiomas. Multidisciplinary approach is highly recommended.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-10-01
DOI
https://doi.org/10.1093/neuonc/noaf193.296
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P09.05.B PARTICLE RE-IRRADIATION FOR THE TREATMENT OF RECURRENT INTRACRANIAL MENINGIOMAS

Silvia Molinelli, S Lillo, Giulia Fontana, Alessia Bazani et al.
Neuro-Oncology
Meningioma and schwannoma management
article

P09.05.B PARTICLE RE-IRRADIATION FOR THE TREATMENT OF RECURRENT INTRACRANIAL MENINGIOMAS

Silvia Molinelli, S Lillo, Giulia Fontana, Alessia Bazani, Alberto Iannalfi, Eleonora Rossi, Ester M. Orlandi, Sara Scardo
article en

Abstract

Abstract BACKGROUND Recurrent intracranial meningiomas have no unique treatment. Particle re-irradiation (reRT) is one of the therapeutic options available and the present study aims at investigating its oncological outcomes. MATERIAL AND METHODS A retrospective analysis was conducted on patients with recurrent intracranial meningiomas treated with both proton and carbon ion reRT from 2016 to 2024. Local control (LC) and overall survival (OS) were evaluated with the Kaplan-Meier method. For prognostic factors analysis the Log-Rank test for testing curve equality was performed and p-value was reported. Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS 20 patients were included, with 11 patients receiving carbon ion reRT and 9 patients receiving proton reRT. With a median follow-up of 22.8 months (range, 4.2-96.2), 5 patients experienced a local relapse after particle reRT. The 1- and 2-year LC was 88.2%, while 5-year LC was 52.3%. A statistically significant difference in terms of median LC was found between grade I and grade II/III meningiomas (40.6 vs 28.4 months, p = 0.0035). OS at 1 and 2 years were respectively 89.5% and 83.1%. There were no grade 3 or higher acute and late toxicities. Four patients developed radiation-induced brain necrosis (RBN), two patients an asymptomatic grade 1 RBN and two patients a grade 2 RBN positively treated with dexamethasone. CONCLUSION Particle reRT is a safe and promising option for recurrent intracranial meningiomas. Multidisciplinary approach is highly recommended.

Neuro-OncologyVol. 27(Supplement_3)
National Center for Oncological Hadrontherapy (IT)
Openalex Percentile: Top 63%
Meningioma and schwannoma management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.